Neurofeedback to reduce return of learned threat expectations

Reducing Spontaneous Recovery Using Functional Connectivity Based Real-time Functional Magnetic Resonance Imaging Neurofeedback Targeting the Memory Control Network

Not applicable Interventional Trustees of Princeton University · NCT07122739

This trial tests whether real-time fMRI neurofeedback of a prefrontal–hippocampal connection can help healthy adults reduce the return of learned threat expectations after extinction.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment40 (estimated)
Ages18 Years to 50 Years
SexAll
SponsorTrustees of Princeton University Academic / other
Locations1 site (Princeton, New Jersey)
Trial IDNCT07122739 on ClinicalTrials.gov

What this trial studies

The study delivers real-time fMRI neurofeedback based on a functional connection between the prefrontal cortex and hippocampus during tasks that model Pavlovian conditioning, extinction, and spontaneous recovery. Healthy adults who demonstrate spontaneous recovery behavior in a prescreen session will be randomized to active or sham neurofeedback. The intervention aims to strengthen inhibitory control over reinstated threat memories by modifying circuit-level connectivity implicated in latent-cause inference and memory suppression. Outcomes include behavioral measures of spontaneous recovery and neuroimaging markers of prefrontal–hippocampal connectivity.

Who should consider this trial

Good fit: Ideal participants are right-handed healthy adults aged 18–50 who are MRI-eligible, have normal color vision and full English reading/writing ability, are not taking psychoactive drugs, and who demonstrate spontaneous recovery behavior on prescreening.

Not a fit: People with psychiatric or neurological disorders, current psychoactive medication use or drug abuse, pregnancy, left-handedness, color blindness, insufficient English comprehension, or who do not show the spontaneous recovery phenotype are unlikely to benefit or be eligible.

Why it matters

Potential benefit: If successful, this approach could reduce the return of fear after exposure and guide new methods to make exposure therapy more durable.

How similar studies have performed: Pilot data and other fMRI neurofeedback studies show preliminary promise, but applying connectivity-based real-time feedback to this specific prefrontal–hippocampal circuit and behavioral phenotype is novel and not yet proven.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adults aged 18-50
* No history of psychiatric disorders or neurological disorders affecting the central nervous system.
* Are not currently taking psychoactive medication or drugs of abuse.
* Must be eligible to enter an MRI (i.e., no permanent metal or medical implants)
* Normal color vision
* Right-handed
* Full reading and writing English comprehension
* Must exhibit spontaneous recovery behavior as determined by an experimenter in a prescreening experimental session
* Must be able to provide informed consent

Exclusion Criteria:

* Pregnancy (female participants)
* Outside of age range
* History of psychiatric or neurological disease
* Currently taking psychoactive medication or drugs of abuse
* Color blindness
* Primary left-handedness
* Less than full reading and writing English comprehension
* Do not exhibit spontaneous recovery behavior as determined by an experimenter in a prescreening experimental session
* Refusing to provide informed consent

Where this trial is running

Princeton, New Jersey

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Healthy
Last reviewed 2026-06-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.